Neuren Pharmaceuticals Limited (ASX: NEU) - Share Price
Current share price for NEU : $16.740 0.26 (1.53%)+
Neuren Pharmaceuticals Limited (NEU), an ASX-listed company, is a biopharmaceutical company developing new drug therapies to treat multiple serious neurological disorders that emerge in early childhood and have no or limited approved treatment options. Recognising the urgent unmet need, all programs have been granted orphan drug designation in the United States.
NEU General Information +
| ASX Code | NEU |
| Website | http://www.neurenpharma.com |
| Industry/Sector | Pharmaceuticals |
| Market Cap ($M) | 2,122 |
| NEU Share Price | $16.740 |
| Day High | $17.200 |
| Day Low | $16.530 |
| Last Close | $17.000 |
| NEU Share Price Movement | $0.26 ( 1.53% ) |
Prices as at 16:40, 3 Jul 2026
+Security prices are delayed by at least 20 minutes and are indicative only.
Neuren Pharmaceuticals Limited (NEU) Upcoming Dividends & Yields
| Distribution Type | Dividend | Franking | Ex-dividend date | Payment date | Current Price+ | Price 7D Avg | Dividend Yield |
|---|
See all dividends from Neuren Pharmaceuticals Limited (NEU) or use our Upcoming Dividends tool to search for dividends across all ASX-listed securities.
Neuren Pharmaceuticals Limited (NEU) price-sensitive announcements
NEU - DAYBU recommended for approval in the European Union
Neuren Pharmaceuticals Limited announced that DAYBU® (trofinetide) has received a positive
Neuren Pharmaceuticals Limited (NEU)
29 Jun 2026 | 7:43 AM
29 Jun 2026 | 7:43 AM
NEU - AGM Chair Address & CEO Presentation
Neuren Pharmaceuticals Limited held its Annual General Meeting on May 27, 2026, highlighti
Neuren Pharmaceuticals Limited (NEU)
27 May 2026 | 1:22 PM
27 May 2026 | 1:22 PM
NEU - Q1 2026 DAYBUE net sales US$101m, up 20% from Q1 2025
In Q1 2026, Neuren Pharmaceuticals Limited reported that DAYBUE® (trofinetide) achieved ne
Neuren Pharmaceuticals Limited (NEU)
7 May 2026 | 9:53 AM
7 May 2026 | 9:53 AM
NEU - DAYBUE STIX now broadly available in US for Rett syndrome
Neuren Pharmaceuticals announced that DAYBUE STIX, a powder formulation of trofinetide, is
Neuren Pharmaceuticals Limited (NEU)
8 Apr 2026 | 9:47 AM
8 Apr 2026 | 9:47 AM
Neuren Pharmaceuticals Limited (NEU) Recent ASX Announcements
NEU Financial Summary
| Year to Dec | NPAT | EPS | EPS chg (%) | PER | DPS | Yield (%) | Franking (%) |
|---|---|---|---|---|---|---|---|
| 2027F | C2 | $55.00 | 120.00% | 30.40 | 0.00 | 0.00% | 0.0% |
| 2026F | C2 | $25.00 | 7.40% | 67.00 | 0.00 | 0.00% | 0.0% |
| 2025A | $30.44 | $23.30 | -78.60% | 67.30 | 0.00 | 0.00% | 0.0% |
NEU Peer Comparison
| Company | Mkt Cap | EPS Growth (%) | P/E (%) | Dividend Yield (%) | ||||||
|---|---|---|---|---|---|---|---|---|---|---|
| 2025 A | 2026 F | 2027 F | 2025 A | 2026 F | 2027 F | 2025 A | 2026 F | 2027 F | ||
| Clarity Pharmaceuticals Ltd (CU6) | $802M | 0.3002 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.00% | 0.00% | 0.00% |
| Neuren Pharmaceuticals Limited (NEU) | $2,155M | -0.7857 | 0.0743 | 1.2000 | 73.0554 | 68.0000 | 30.9091 | 0.00% | 0.00% | 0.00% |
NEU Market Comparison
| Earnings | P/E Ratio | P/B Ratio | P/E Growth | |
|---|---|---|---|---|
| Company | 0.75 | 69.30 | 6.26 | 1.29 |
| Market | 0.29 | 13.10 | 1.15 | 0.63 |
| Sector | 0.46 | 26.30 | 2.44 | 1.86 |
NEU Directors
| Name | Position | Start Date |
|---|---|---|
| Mr Jonathan (Jon) Charles Pilcher | Chief Executive Officer, Managing Director | 14 Jun 2021 |
| Ms Dianne Margaret Angus | Non-Executive Director | 1 Jul 2018 |
| Dr Jenny Lee Harry | Non-Executive Director | 7 Jul 2018 |
| Mr Joseph(Joe) Basile | Non-Executive Director | 2 Mar 2023 |
| Mr Patrick Davies | Non-Executive Director, Non-Executive Chairman | 1 Jul 2018 |
Neuren Pharmaceuticals Limited (NEU) Changes in Directors' Interest & Trades
| Date of change | Director | Buy/Sell | Security Type | Qty | Trade Price | Value |
|---|---|---|---|---|---|---|
| 5 Mar 2026 | BASILE, Joseph(Joe) | Buy | Direct Shares | 12,300 | $12.340 | $151,782.000 |
| 8 Sep 2025 | PILCHER, Jonathan (Jon) | Sell | Indirect Shares | 398,207 | $20.000 | $7,964,140.000 |
| 22 Jul 2025 | PILCHER, Jonathan (Jon) | Buy | Direct Shares | 1,500,000 | $1.840 | $2,760,000.000 |
See all changes in directors' interest & trades for Neuren Pharmaceuticals Limited (NEU) or use our Changes in directors' interest tool to search for changes & trades across all ASX-listed securities.
NEU Management
| Name | Position |
|---|---|
| Gerry Zhao | Chief Business Officer |
| Lauren Frazer | Chief Financial Officer,Company Secretary |
| Liza Squires | Chief Medical Officer |
| Clive Blower | Chief Operations Officer |
| Daryl Dekarske | Chief Regulatory Officer |
| Larry Glass | Chief Science Officer |
NEU Substantial Shareholders
Under ASX rules large investors and investment funds must disclose when they own more than a 5% stake in Neuren Pharmaceuticals Limited (NEU). However, you won't necessarily see their names in the company’s annual report, as many trade under nominee names. These shareholders are obliged to provide ongoing substantial notices relating to any change of 1% or more.
| Holding | Name |
|---|---|
| 6,492,295 (5.02%) | Vanguard Group |
| 6,412,618 (5.01%) | State Street Corporation and subsidiaries |
NEU Calendar of Events
| Date | Event |
|---|---|
| 23 April 2027 | Report (Annual) |
| 26 February 2027 | Report (Prelim) |
| 26 August 2026 | Report (Interim) |
DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.
Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate,
complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892)
and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and,
if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest.
No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser.
Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.
What our members say about us
Proudly
We're here to help
Call 1300 880 160
Start a chat
Schedule a call
